Company Profile

Auxagen Inc
Profile last edited on: 8/22/16      CAGE: 47A01      UEI: J74LH5EBZDA9

Business Identifier: Treatment and prevention of various diseases using TGF-β receptor antagonists & enhancers
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

4041 Forest Park Ave.
Saint Louis, MO 63108
   (314) 633-1860
Location: Single
Congr. District: 01
County: St. Louis city

Public Profile

Auxagen Inc was founded to develop therapeutic agents based on newly developed technologies of TGF-β receptor antagonists and TGF-β enhancers for the treatment of wounds and tissue fibrosis which currently lacked effective therapy. Transforming growth factor-β (TGF-β) is a family of structurally homologous dimeric proteins that regulate multiple biological processes such as cell production, extracellular matrix (ECM) synthesis, angiogenesis, immune responses, apoptosis and differentiation. They have also been associated with the development of chronic wounds, tissue fibrosis, cardiovascular disease, cancer, autoimmune diseases, and other disorders. As of 2014, two products, a gel formulation for wound treatment and a aerosol formulation for treatment of lung fibrosis, are in pre-clinical tria

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
Less than .5M
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2016 1 NIH $283,567
Project Title: A Novel TGF-Receptor Antagonist to Treat Pulmonary Fibrosis
2011 2 NIH $1,173,514
Project Title: TGF-Beta Antagonists for Accelerating Wound Healing
2009 1 NIH $227,692
Project Title: A Therapeutic Agent For Radiation-Induced Lung Fibrosis
2008 1 NIH $182,189
Project Title: Novel Therapeutic Agents For Diabetic Ulcers
2007 1 NIH $199,467
Project Title: Novel Antagonists for Ameliorating Pulmonary Fibrosis

Key People / Management

  Shuan S Huang -- President; Research Director

  Jung S Huang -- Founder

  Michael W Huang -- Chief Executive Officer

Company News

There are no news available.